Clinical Cancer Research, Vol 3, Issue 8 1299-1308, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Vitronectin binding to urokinase receptor in human breast cancer

MV Carriero, S Del Vecchio, P Franco, MI Potena, F Chiaradonna, G Botti, MP Stoppelli and M Salvatore
Istituto Nazionale per lo Studio e la Cura dei Tumori, Via M. Semmola.

Functional assembly of the plasminogen-dependent proteolytic system on the cell surface requires multiple interactions involving urokinase (uPA), urokinase receptor (uPAR), plasminogen activator inhibitors, and other molecules that mediate cell migration and adhesion. We analyzed the in vitro interaction of uPAR-containing particulate cell fractions with the amino-terminal fragment (ATF) of human urokinase and the matrix-like form of vitronectin. Binding and cross-linking of 125I-labeled ATF to crude membrane extracts from LB6-19 mouse cells overexpressing human uPARs in the presence of 25 nM urea-denatured vitronectin led to the formation of Mr 137,000, 92, 000, and 82,000 covalent complexes. Immunoprecipitation of the preformed cross-linked 125I-labeled complexes with anti-vitronectin, anti-uPA, or anti-uPAR antibodies revealed that the Mr 82,000 and 92, 000 species do contain ATF and vitronectin and identified the Mr 137, 000 species as a ternary complex formed by ATF, uPAR, and vitronectin. A similar electrophoretic pattern was displayed by acid-pretreated membranes extracted from MCF-7 breast carcinoma or HT1080 fibrosarcoma cell lines, as well as a ductal breast carcinoma specimen; the latter exhibited complex formation at concentrations of vitronectin lower than 10 nM. Finally, uPAR-vitronectin interaction was further documented by the decreased reactivity of an anti-uPAR polyclonal antibody to acid-pretreated sections of 10 breast carcinomas that had been preincubated with vitronectin. Our findings highlight the ability of uPAR to interact simultaneously with vitronectin and uPA in breast cancer, supporting a dynamic coupling of the molecular mechanisms underlying plasminogen-dependent matrix degradation and cell adhesion.

This article has been cited by other articles:

				B. G. Hollier, J. A. Kricker, D. R. Van Lonkhuyzen, D. I. Leavesley, and Z. Upton Substrate-Bound Insulin-Like Growth Factor (IGF)-I-IGF Binding Protein-Vitronectin-Stimulated Breast Cell Migration Is Enhanced by Coactivation of the Phosphatidylinositide 3-Kinase/AKT Pathway by {alpha}v-Integrins and the IGF-I Receptor Endocrinology, March 1, 2008; 149(3): 1075 - 1090. [Abstract] [Full Text] [PDF]

				P. Franco, I. Vocca, M. V. Carriero, D. Alfano, L. Cito, I. Longanesi-Cattani, P. Grieco, L. Ossowski, and M. P. Stoppelli Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and {alpha}v{beta}5 integrin J. Cell Sci., August 15, 2006; 119(16): 3424 - 3434. [Abstract] [Full Text] [PDF]

				L. Gargiulo, I. Longanesi-Cattani, K. Bifulco, P. Franco, R. Raiola, P. Campiglia, P. Grieco, G. Peluso, M. P. Stoppelli, and M. V. Carriero Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide J. Biol. Chem., July 1, 2005; 280(26): 25225 - 25232. [Abstract] [Full Text] [PDF]

				V. Rajagopal and R. J. Kreitman Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the alpha 2-Macroglobulin Receptor J. Biol. Chem., March 10, 2000; 275(11): 7566 - 7573. [Abstract] [Full Text] [PDF]

				A. Zannetti, S. Del Vecchio, M. V. Carriero, R. Fonti, P. Franco, G. Botti, G. D’Aiuto, M. P. Stoppelli, and M. Salvatore Coordinate Up-Regulation of Sp1 DNA-binding Activity and Urokinase Receptor Expression in Breast Carcinoma Cancer Res., March 1, 2000; 60(6): 1546 - 1551. [Abstract] [Full Text]

				M. V. Carriero, S. D. Vecchio, M. Capozzoli, P. Franco, L. Fontana, A. Zannetti, G. Botti, G. D'Aiuto, M. Salvatore, and M. P. Stoppelli Urokinase Receptor Interacts with {{alpha}}v{{beta}}5 Vitronectin Receptor, Promoting Urokinase-dependent Cell Migration in Breast Cancer Cancer Res., October 1, 1999; 59(20): 5307 - 5314. [Abstract] [Full Text] [PDF]

				P. Franco, O. Massa, M. Garcia-Rocha, F. Chiaradonna, C. Iaccarino, I. Correas, E. Mendez, J. Avila, F. Blasi, and M. P. Stoppelli Protein Kinase C-dependent in Vivo Phosphorylation of Prourokinase Leads to the Formation of a Receptor Competitive Antagonist J. Biol. Chem., October 16, 1998; 273(42): 27734 - 27740. [Abstract] [Full Text] [PDF]

				T. Chavakis, S. M. Kanse, B. Yutzy, H. R. Lijnen, and K. T. Preissner Vitronectin Concentrates Proteolytic Activity on the Cell Surface and Extracellular Matrix by Trapping Soluble Urokinase Receptor-Urokinase Complexes Blood, April 1, 1998; 91(7): 2305 - 2312. [Abstract] [Full Text] [PDF]

				S. Liu, T. H. Bugge, and S. H. Leppla Targeting of Tumor Cells by Cell Surface Urokinase Plasminogen Activator-dependent Anthrax Toxin J. Biol. Chem., May 18, 2001; 276(21): 17976 - 17984. [Abstract] [Full Text] [PDF]